Zobrazeno 1 - 10
of 215
pro vyhledávání: '"bispecific T cell engagers"'
Autor:
Jianhua Ding, Chaihong Yeong
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Small cell lung cancer (SCLC) remains one of the most aggressive and challenging malignancies to treat, with limited therapeutic options and poor outcomes. Recent advances in understanding SCLC biology have identified Delta-like ligand 3 (DLL3) as a
Externí odkaz:
https://doaj.org/article/eb7487eae32f47ef93a0a88721f0326f
Autor:
Anaïs Jiménez-Reinoso, Magdalena Molero-Abraham, Cristina Cirauqui, Belén Blanco, Eva M. Garrido-Martin, Daniel Nehme-Álvarez, Carmen Domínguez-Alonso, Ángel Ramírez-Fernández, Laura Díez-Alonso, Ángel Nuñez-Buiza, África González-Murillo, Raquel Tobes, Eduardo Pareja, Manuel Ramírez-Orellana, José Luis Rodriguez-Peralto, Irene Ferrer, Jon Zugazagoitia, Luis Paz-Ares, Luis Álvarez-Vallina
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Adoptive transfer of tumor-infiltrating lymphocytes (TIL) has shown remarkable results in melanoma, but only modest clinical benefits in other cancers, even after TIL have been genetically modified to improve their tumor homing, cytotoxic potential o
Externí odkaz:
https://doaj.org/article/e8672f59553649e1a19d8ee020cd28b0
Autor:
Daniele Caracciolo, Antonia Mancuso, Nicoletta Polerà, Caterina Froio, Giuseppe D’Aquino, Caterina Riillo, Pierosandro Tagliaferri, Pierfrancesco Tassone
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-19 (2023)
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is a challenging pediatric and adult haematologic disease still associated with an unsatisfactory cure rate. Unlike B-ALL, the availability of novel therapeutic options to definitively improve the
Externí odkaz:
https://doaj.org/article/3b99e086523247df91018fd0cf77844f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Andrea Lombardi, Atil Saydere, Riccardo Ungaro, Giorgio Bozzi, Giulia Viero, Alessandra Bandera, Andrea Gori, Mario U. Mondelli
Publikováno v:
International Journal of Infectious Diseases, Vol 120, Iss , Pp 77-82 (2022)
Background: Immunological treatments (immune checkpoint inhibitors [ICIs], chimeric antigen receptor T [CAR-T] cells, bispecific T-cell engagers [BiTEs]) have deeply changed the treatment of several cancers. However, the impact of these treatments on
Externí odkaz:
https://doaj.org/article/0e02aac872264de398e27c4cd37f2117
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient’s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, a
Externí odkaz:
https://doaj.org/article/9151fa92203443fea21761bcebd7f147
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a
Externí odkaz:
https://doaj.org/article/37fde7de4e554d8ea6617fff671bc7bf
Autor:
Qiuman Wang, Xinyue Ma, Huan Wu, Chen Zhao, Jingying Chen, Rongrong Li, Shi Yan, Yingwei Li, Qing Zhang, Kun Song, Cunzhong Yuan, Beihua Kong
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The improved survival rate of ovarian cancer (OC) is related to the action of infiltrating cytotoxic T lymphocytes (CTLs). Recently, oncolytic adenoviruses (OAds) have emerged as a key player in treating solid tumors; however, the immunosuppressive t
Externí odkaz:
https://doaj.org/article/e928d55ffab7493f95683a8999ae39bb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-24 (2021)
Abstract Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavailability and severe toxicities hav
Externí odkaz:
https://doaj.org/article/17f684d9d71746339f5189e4f47a4dd7